Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-04-10
2007-04-10
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S141100
Reexamination Certificate
active
10428360
ABSTRACT:
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM′) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM′ allows the use of an immunoenzymatic assay for their detection.
REFERENCES:
patent: 5036003 (1991-07-01), Olander et al.
patent: 5153118 (1992-10-01), Wright, Jr. et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5643786 (1997-07-01), Cohen et al.
patent: 5773292 (1998-06-01), Bander
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6194152 (2001-02-01), Laus et al.
patent: 2004/0033229 (2004-02-01), Maddon et al.
patent: 0 228 243 (1987-07-01), None
patent: WO 94/02156 (1994-02-01), None
patent: WO 96/09820 (1994-05-01), None
patent: WO 96/08570 (1996-03-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO-97/35616 (1997-10-01), None
patent: WO 98/03873 (1998-01-01), None
patent: WO-99/47554 (1999-09-01), None
patent: WO 02/069907 (2002-09-01), None
patent: WO-03/034903 (2003-05-01), None
patent: WO 03/064606 (2003-08-01), None
US 6,290,956, 09/2001, Bander (withdrawn)
Pohl et al (1993, Int. J. Cancer, vol. 54, pp. 820-827).
Introduction to Chemotherapy downloaded from the site of http, training.seer.cancer.gove on Oct. 15, 2005.
Beutler et al., L-Glutamate, Colorimetric Method with Glutamate Dehydrogenase and Diaphorase, Methods of Enzymatic Analysis, Bergmeyer et al., Eds, 1985 VCH Publishers, Deerfield Beach, pp. 369-376.
Ruth E. Carter et al., Prostate-specific membrane antigen is a hydrolase with substrate and pharacologic characteristics of a neuropeptidase, Proc. Natl. Acad. Sci. USA, Jan. 1996;93:749-753.
Fernandez et al., Influence of Epitope Polarity and Adjuvants on the Immunogenicity and Efficacy of a Synthetic Peptide Vaccine Against Semliki Forest Virus, Journal of Virology, 1993;67:5843-8.
Fernandez et al., Epitope Polarity and Adjuvants Influence the Fine Specificity of the Humoral Response Against Emliki Forest Virus Specific Peptide Vaccines, Vaccine, 1998;16:1531-6.
He Liu et al., Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium, Cancer Research, 1997;57-3629-3634.
Horoszewicz et al., Monoclonal Antibodies to a New Antigenic Marker in Epthelial Prostatic Cells and Serum of Prostatic Cancer Patients, Anticancer Research, 1987;7:927-936.
Israeli et al., Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen, Cancer Research, 1993;53:227-230.
Leek et al., Prostate-specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene, British Journal of Cancer, 1995;72:583-588.
G.P. Murphy et al.., Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody, The Prostate, 1996;28:266-271.
G.P. Murphy et al., Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients with Benign Prostatic Enlargement, The Prostate, 1995;26:164-168.
G.P. Murphy et al., Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients, Anticancer Res., 1995;15:1473-1480.
Nakamura et al., Enzyme immunoassays: heterogeneous and homogeneous systems, Handbook of Exp. Immunol., Weir et al., Eds., Blackwell Scientific Publications, Oxford, 1997;1:2711-2720.
Rochon et al., Western Blot Assay for Prostate Specific Membrane Antigen in Serum of Prostate Cancer Patients, The Prostate, 1994;25:219-223.
Roitt et al., Immunology, 3rdEd., Mosby, St. Louis, p. 106 (1993).
Robert M. Sharkey et al., Enhanced Clearance of Radiolabeled Murine Monoclonal Antibody by a Syngeneic Anti-Idiotype Antibody in Tumor-bearing Nude Mice, Int. J. Cancer, 1992;51:266-273.
Sai L. Su et al., Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA:Ratio of Expression as a Potential Measurement of Progression, Cancer Research, Apr. 1, 1995;55:1441-1443.
Benjamin Tjoa et al., In Vitro Propagated Dendritic Cells From Prostate Cancer Patients as a Component of Prostate Cancer Immunotherapy, The Prostate, 1995;27:63-69.
Troyer et al., Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids, Int. J. Cancer, 1995;62:552-558.
Troyer et al., Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen, Urol. Oncol., 1995;1:29-37.
Troyer et al., Subcellular Localization of the 7E11-C5 Prostate Specific Antigen, Proc. Am. Assoc. Cancer Res., 1994; 35:283, Abstract 1688.
Wright et al., Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5, Antibody Immunoconjugates and Radio Pharmaceuticals 3: Abstract 193 (1990).
Bruggeman, M., et al., “Dtrategies for expressing human antibody repertoires in transgenic mice,”Immunol. Today, 17(8):391-97 (Aug. 17, 1996).
Curnow, RT. “Clinical experience wit CD64-directed immunotherapy. An overview.”Cancer Immunol. Immunoither., 45(3-4):210-15 (Nov.-Dec. 1997).
Gong, M.C., et al., “Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers,”Cancer Metastasis Rev., 18(4):483-90 (1999).
Green, L.L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,”J. Immunol. Methods, 231(1-2): 11-23 (Dec. 10, 1999).
Hamilton, A. et al., “A novel humanised antibody against Prostate Specific Membrane Antigen (PSMA) for in vivo targeting and therapy.” Proceedings of the American Association for Cancer Research Annual Meeting; 89th Annual Meeting of the American Association for Cancer Research; New Orleans, Louisiana, USA. vol. 39 (Mar. 1998).
Vaughn, TJ, et al., “Human antibodies by design.”Natl. Biotechnol., 16(6):535-9 (Jun. 1998).
Boynton Alton L.
Holmes Eric H.
Murphy Gerald P.
Tino William T
Lahive & Cockfield LLP
Medarex Inc.
Yu Misook
LandOfFree
Monoclonal antibodies specific for the extracellular domain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies specific for the extracellular domain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies specific for the extracellular domain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754435